Atypical chronic myeloid leukemia (aCML) shares clinical and laboratory features with CML,
but it lacks the BCR-ABL1 fusion. We performed exome sequencing of eight aCMLs and …

Imatinib is effective for the treatment of chronic myeloid leukemia (CML). However even
undetectable BCR‐ABL1 by Q‐RT‐PCR does not equate to eradication of the disease. Digital‐…

The association between physical exercise and oxidative damage in the skeletal musculature
has been the focus of many studies in literature, but the balance between superoxide …

Despite the recent identification of recurrent SETBP1 mutations in atypical chronic myeloid
leukemia (aCML), a complete description of the somatic lesions responsible for the onset of …

Objective To evaluate the effects of nusinersen on respiratory function of patients with type 1
spinal muscular atrophy. Study design Observational, longitudinal cohort study. We …

A 90 nm 4 Mb embedded phase-change memory (PCM) is presented, demonstrating the
feasibility of PCM integration with 3 masks overhead in a 6-ML standard CMOS process. Using …

The study reports real world data in type 2 and 3 SMA patients treated for at least 2 years
with nusinersen. Increase in motor function was observed after 12 months and during the …

A novel class of filters (called pipe filters) that features in-band noise reduction is presented
and a current mode biquad cell based on cross-connected cascoded devices is introduced. …

ALK is a tyrosine kinase receptor involved in a broad range of solid and hematologic tumors.
Among 70% to 80% of ALK + anaplastic large cell lymphomas (ALCL) are caused by the …

SETBP1 variants occur as somatic mutations in several hematological malignancies such
as atypical chronic myeloid leukemia and as de novo germline mutations in the Schinzel–…